Cilostazol is included in the database.|Pletal is indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. /Included in US product label/|Because of its antiplatelet activity, cilostazol has been used alone or in combination with other ...
Accordingly, cilostazol shows superior effects for the treatment or prevention of alcoholic liver diseases, in particular, alcoholic hepatitis compared to pentoxifylline which is conventionally used as a therapeutic agent for the treatment for alcoholic hepatitis. Thus, cilostazol is suitable for use as ...
Importance of providing patient a copy of manufacturer’s patient information each time therapy is prescribed. Importance of adherence to prescribed directions for use. Importance of not taking cilostazol if CHF (e.g., shortness of breath, swelling of the legs) is present. Importance of taking ...
Cilostazol-d4is intended for use as an internal standard for the quantification of cilostazol by GC- or LC-MS. Cilostazol is a phosphodiesterase 3A (PDE3A) inhibitor (IC50= 0.2 µM for the platelet enzyme).1It is selective for PDE3A over PDE1, -2, -4, and 5 (IC50s = >5 µM...
A significant increase of FMD values in the cilostazol group is seen, while not in the aspirin group Full size image Factors associated with FMD at T1 in cilostazol group In the multiple linear regression analysis for evaluation of factors associated with increase in FMD values at T1, factors ...
1 Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is widely used in the acute stage of stroke to reduce the incidence of recurrent ischemic stroke.2 Short-term use of DAPT for 21–90 days after stroke onset has been shown to efficiently reduce the risk of recurrent stroke, ...
Cilostazol (CS), 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3, 4-dihydro-2-(1H)-quinolinone, is a potent selective phosphodiesterase type III inhibitor. CS functions as a platelet aggregation inhibitor16and vasodilator,17and is mainly used for treating patients with peripheral arterial dise...
In addition, MCP-1 is a crucial factor for the development of atherosclerosis. Whereas VCAM-1 exerts a dominant role in the ini- tiation of atherosclerosis, increased MCP-1 ex- pression was demonstrated to mediate chronic inflammation. Both preferentially contribute to mon- ocyte adhesion (Lee ...
Cilostazol for intermittent claudication. In: Cleanthis M, editor. Cochrane database Syst. Rev. Chichester: Wiley; 2014.Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014. https://doi.org...
Background and purpose: Cilostazol is a specific inhibitor of 3′-5′-cyclic adenosine monophosphate (cAMP) phosphodiesterase, which is widely used to treat ischemic symptoms of peripheral vascular disease. Although cilostazol has been shown to exhibit vasodilator p...